Judge Rules Pfizer's Lyrica Patents Are Valid

Law360, New York (July 19, 2012, 10:12 PM EDT) -- The patents for Pfizer Inc.'s blockbuster nerve pain drug Lyrica are valid, meaning Teva Pharmaceuticals Industries Ltd., Mylan Pharmaceuticals Inc. and others can't sell their planned generic versions, a Delaware federal judge said Thursday.

U.S. District Judge Gregory M. Sleet ruled that Pfizer and Northwestern University's three patents for Lyrica were not obvious, anticipated or invalid for any other reason, and issued an injunction banning Teva, Mylan and others from marketing no-name versions of the drug before it expires in 2018.

Lyrica, which was designed to...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.